N-propyl-3-(trifluoromethyl)benzamide | 53743-25-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-propyl-3-(trifluoromethyl)benzamide
• CAS: 53743-25-2
• 化学式: C₁₁H₁₂F₃NO
• mdl: MFCD00243810
• 分子量: 231.218
• InChiKey: OPQNVKBIBGFOCD-UHFFFAOYSA-N

物化性质

• 保留指数：
  1526

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  对甲苯磺酰叠氮 、 N-propyl-3-(trifluoromethyl)benzamide 在 silver hexafluoroantimonate 、 bis[dichloro(pentamethylcyclopentadienyl)iridium(III)] 、 lithium carbonate 、 溶剂黄146 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 12.0h， 以99%的产率得到2-((4-methylphenyl)sulfonamido)-N-propyl-5-(trifluoromethyl)benzamide
  参考文献：
  名称：

  Iridium-Catalyzed Direct C–H Amidation Producing Multicolor Fluorescent Molecules Emitting Blue-to-Red Light and White Light

  摘要：

  We report a powerful strategy, iridium-catalyzed direct C-H amidation (DCA) for synthesizing various fluorescent sulfonamides that emit light over the entire visible spectrum with excellent efficiency (up to 99% yields). By controlling electronic characters of the resulting sulfonamides, a wide range of blue-to-red emissions was predictably obtained via an excited-state intramolecular proton-transfer process. Furthermore, we even succeeded in a white-light generation, highlighting that this DCA is an excellent synthetic method to prepare a library of fluorophores.

  DOI：

  10.1021/acs.orglett.0c00618
• 作为产物：
  描述：

  正丙胺 、 3-(三氟甲基)苯甲酰氯 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以99%的产率得到N-propyl-3-(trifluoromethyl)benzamide
  参考文献：
  名称：

  Iridium-Catalyzed Direct C–H Amidation Producing Multicolor Fluorescent Molecules Emitting Blue-to-Red Light and White Light

  摘要：

  We report a powerful strategy, iridium-catalyzed direct C-H amidation (DCA) for synthesizing various fluorescent sulfonamides that emit light over the entire visible spectrum with excellent efficiency (up to 99% yields). By controlling electronic characters of the resulting sulfonamides, a wide range of blue-to-red emissions was predictably obtained via an excited-state intramolecular proton-transfer process. Furthermore, we even succeeded in a white-light generation, highlighting that this DCA is an excellent synthetic method to prepare a library of fluorophores.

  DOI：

  10.1021/acs.orglett.0c00618

文献信息

• [EN] PHARMACEUTICALLY ACTIVE PYRAZOLO-PYRIDONE MODULATORS OF DCN1/2-MEDIATED CULLIN NEDDYLATION<br/>[FR] MODULATEURS DE PYRAZOLO-PYRIDONE PHARMACEUTIQUEMENT ACTIFS DE NÉDDYLATION INDUITE PAR DCN1/2
  申请人：UNIV KENTUCKY RES FOUND

  公开号：WO2020257790A1

  公开（公告）日：2020-12-24

  A DCN1/2-mediated cullin neddylation modulator; a method for treating disorders associated with dysfunctional DCN1 and/or UBC12, Alzheimer's disease, other neurodegenerative diseases, bacterial infections, or viral infections; and a method for treating cancers are provided. The DCN1/2-mediated cullin neddylation modulator includes a compound according to Formula I disclosed herein. The methods include administering to a mammal a therapeutically effective amount of a compound according to Formula I. Also provided herein is a pharmaceutical composition including a therapeutically effective amount of a compound according to Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

  提供了一种由DCN1/2介导的cullin泛素化调节剂；一种治疗与DCN1和/或UBC12功能失调相关的疾病、阿尔茨海默病、其他神经退行性疾病、细菌感染或病毒感染的方法；以及一种治疗癌症的方法。DCN1/2介导的cullin泛素化调节剂包括本文披露的一种符合式I的化合物。该方法包括向哺乳动物施用符合式I的化合物的治疗有效剂量。本文还提供了一种包括符合式I的化合物的治疗有效剂量或其药学上可接受的盐以及药学上可接受的载体的药物组合物。
• QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS
  申请人：Collingwood Stephen Paul

  公开号：US20100041887A1

  公开（公告）日：2010-02-18

  Compounds of formula I in salt or zwitterionic form wherein, wherein R 1 , R 2 , R 3 , and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  具有式I的化合物，其以盐或双离子形式存在，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由肌肉乙酰胆碱M3受体介导的疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• Quinuclidine derivatives binding to mucarinic m3 receptors
  申请人：Collingwood Paul Stephen

  公开号：US20070060563A1

  公开（公告）日：2007-03-15

  Compounds of formula I in salt or zwitterionic form wherein, wherein R 1 , R 2 , R 3 , and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  具有式I的盐或双电离形式的化合物，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由肌肉型M3受体介导的病症。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20140221357A1

  公开（公告）日：2014-08-07

  The present invention provides compounds of Formula (I) or Formula (III): [INSERT CHEMICAL STRUCTURE HERE] (I) [INSERT CHEMICAL STRUCTURE HERE] (III) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

  本发明提供了式(I)或式(III)的化合物：[在此插入化学结构] (I) [在此插入化学结构] (III)，其定义在说明书中，并包括任何此类新化合物的组合物。这些化合物是内皮脂肪酶抑制剂，可用作药物。
• Substituted Imidazopyridazines as Lipid Kinase Inhibitors
  申请人：Capraro Hans-Georg

  公开号：US20100305113A1

  公开（公告）日：2010-12-02

  The invention relates to novel compounds of the formula I, as well as other invention embodiments related to these compounds. The compounds are e.g. useful in the treatment of the animal or human body in view of their ability to inhibit protein kinases such as especially PI3 kinase.

  本发明涉及公式I的新化合物，以及与这些化合物相关的其他发明实施方式。这些化合物可用于治疗动物或人体，因为它们能够抑制蛋白激酶，特别是PI3激酶。